# Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

Study · id `cardio:ct-nct01876368` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01876368](<https://clinicaltrials.gov/study/NCT01876368>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01876368

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 376 participants.

## Technical summary

Registry record NCT01876368. Randomized; double masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-12-07.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 376 participants (enrolled count; ClinicalTrials.gov record NCT01876368, source copy `cardio:ctgov-nct01876368-2015-12-07`, retrieved 2026-10-26)
- Start date: 2013-09 (registry gives no type) (ClinicalTrials.gov record NCT01876368, source copy `cardio:ctgov-nct01876368-2015-12-07`, retrieved 2026-10-26)
- Primary completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01876368, source copy `cardio:ctgov-nct01876368-2015-12-07`, retrieved 2026-10-26)
- Completion: 2014-08 (actual) (ClinicalTrials.gov record NCT01876368, source copy `cardio:ctgov-nct01876368-2015-12-07`, retrieved 2026-10-26)
- Results first posted: 2015-12-07 (ClinicalTrials.gov record NCT01876368, source copy `cardio:ctgov-nct01876368-2015-12-07`, retrieved 2026-10-26)
- Countries: United States; Argentina; Guatemala; Philippines; Puerto Rico; Russia; Spain (ClinicalTrials.gov record NCT01876368, source copy `cardio:ctgov-nct01876368-2015-12-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01876368-2015-12-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
- Condition: Hypertension
- Intervention (Drug): LCZ696
- Intervention (Drug): Olmesartan
- Intervention (Drug): Placebo of LCZ696
- Intervention (Drug): Placebo of Olmesartan
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Sacubitril/valsartan (combination) (`cardio:sacubitril-valsartan`)
- Registry intervention name matches this record: Olmesartan (`cardio:olmesartan`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 5c4923eac9f85ab71f1ba8b1231a5af0dd971bde392b81d96b4c2694c514df51
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
